Treatment with 200 mg/d of Eriomin significantly decreased blood glucose (−5%), homeostasis model assessment of insulin resistance (−11%), glucagon (−13%), interleukin-6 (−14%), tumor necrosis factor alpha (−20%), and alkaline phosphatase (−13%); but increased glucagon-like peptide 1 (GLP-1) by (17%) (P ≤ .05). The gene discussed is IL6; the disease is Insulin resistance.